Hyaluronidase: Its effects on HI-6 dichloride and dimethanesulphonate pharmacokinetic profile in pigs

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10146026" target="_blank" >RIV/00179906:_____/13:10146026 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/13:10146026 RIV/60162694:G44__/13:43874788

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0378427413001689" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0378427413001689</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.toxlet.2013.04.013" target="_blank" >10.1016/j.toxlet.2013.04.013</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Hyaluronidase: Its effects on HI-6 dichloride and dimethanesulphonate pharmacokinetic profile in pigs

Popis výsledku v původním jazyce

Pigs were administered intramuscularly molar equivalents of HI-6 salts (HI-6 dichloride 10.71 mg/kg and HI-6 DMS 13.59 mg/kg) either with or without hyaluronidase (60 U/kg). Hyaluronidase is supposed to increase tissue permeability and diminishes discomfort caused by the intramuscular injection. Doses of HI-6 salts corresponded with standard HI-6 dichloride dose in one autoinjector (500 mg) and were recalculated for 1 kg of body weight. According to the results, both HI-6 salts applied in combination with hyaluronidase had increased tissue absorption and improved pharmacokinetic profile. The Cmax was significantly higher in case of HI-6 DMS plus hyaluronidase (29.6 +- 2.98 ?g/ml) administration increase compared to HI-6 DMS (23.8 +- 3.04 ?g/ml) and HI-6 dichloride (19.0 +- 0.93 ?g/ml); both without hyaluronidase. Bioavailability calculated as AUCtotal (HI-6 DMS with hyaluronidase, 4119 +- 647 min ?g/ml) was also significantly higher compared to HI-6 DMS (2259 +- 329 min ?g/ml) and HI-6

Název v anglickém jazyce

Hyaluronidase: Its effects on HI-6 dichloride and dimethanesulphonate pharmacokinetic profile in pigs

Popis výsledku anglicky

Pigs were administered intramuscularly molar equivalents of HI-6 salts (HI-6 dichloride 10.71 mg/kg and HI-6 DMS 13.59 mg/kg) either with or without hyaluronidase (60 U/kg). Hyaluronidase is supposed to increase tissue permeability and diminishes discomfort caused by the intramuscular injection. Doses of HI-6 salts corresponded with standard HI-6 dichloride dose in one autoinjector (500 mg) and were recalculated for 1 kg of body weight. According to the results, both HI-6 salts applied in combination with hyaluronidase had increased tissue absorption and improved pharmacokinetic profile. The Cmax was significantly higher in case of HI-6 DMS plus hyaluronidase (29.6 +- 2.98 ?g/ml) administration increase compared to HI-6 DMS (23.8 +- 3.04 ?g/ml) and HI-6 dichloride (19.0 +- 0.93 ?g/ml); both without hyaluronidase. Bioavailability calculated as AUCtotal (HI-6 DMS with hyaluronidase, 4119 +- 647 min ?g/ml) was also significantly higher compared to HI-6 DMS (2259 +- 329 min ?g/ml) and HI-6

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12062" target="_blank" >NT12062: Příprava a hodnocení účinnosti nových terapeutik proti otravám pesticidy</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Toxicology Letters

ISSN

0378-4274

e-ISSN

—

Svazek periodika

220

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

5

Strana od-do

167-171

Kód UT WoS článku

000320595100009

EID výsledku v databázi Scopus

—